Topical Safety Study of Topical Diltiazem Hydrochloride

Ventrus Biosciences

Status and phase: Unknown; Phase 1

Conditions: Diltiazem Skin Sensitivity.

Treatments: Drug: Saline (0.9%); Drug: Vehicle Cream; Drug: 0.1% solution of sodium lauryl sulfate (SLS); Drug: Diltiazem Hydrochloride 2% Cream

Study type: Interventional

Funder types: Industry

Identifiers

NCT01816529

VEN307-DERM-001

Details and patient eligibility

About

The goal of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions.

Full description

The primary objective of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream and its vehicle to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions. In addition, the irritation potential of the investigational products will be assessed during the Induction Phase and safety will be assessed by evaluation of any adverse events (AEs) reported during the study.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are healthy males or females (to be confirmed by medical history);
• Are 18 years of age or older;
• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
• In the case of females of childbearing potential: have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at the end of study (EOS);
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
• Read, understand, and provide signed informed consent.

Exclusion criteria

• Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs);
• Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history);
• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
• Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
• Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
• Have psoriasis and/or active atopic dermatitis/eczema;
• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
• Have a known sensitivity to constituents present in the material being evaluated;
• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
• Have received treatment for any type of internal cancer within 5 years prior to study entry;
• Have a history of, or are currently being treated for skin cancer;
• Are currently participating in any clinical testing,
• Have any known sensitivity to adhesives; and/or
• Have received any investigational treatment(s) within 4 weeks prior to study entry.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Triple Blind

---

200 participants in 4 patient groups, including a placebo group

Topical Diltiazem Hydrochloride 2% Cream

Experimental group

Description:

0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Treatment:

Drug: Diltiazem Hydrochloride 2% Cream

Vehicle Cream

Placebo Comparator group

Description:

0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Treatment:

Drug: Vehicle Cream

0.1% solution of sodium lauryl sulfate (SLS)

Active Comparator group

Description:

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Treatment:

Drug: 0.1% solution of sodium lauryl sulfate (SLS)

0.9% Saline

Placebo Comparator group

Description:

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Treatment:

Drug: Saline (0.9%)